Litigation Details for VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2023)

VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2023)

Docket		Date Filed	2023-01-29
Court	District Court, D. New Jersey	Date Terminated	2023-12-26
Cause	15:1125 Trademark Infringement (Lanham Act)	Assigned To	Michael E. Farbiarz
Jury Demand	Plaintiff	Referred To	Jessica S. Allen
Parties	VANDA PHARMACEUTICALS INC.
Patents	10,149,829; 10,179,119; 10,610,510; 10,610,511; 10,980,770; 11,141,400; 11,266,622; 11,285,129; 9,539,234; 9,730,910
Attorneys	LIZA M. WALSH
Firms	Robinson Miller LLC, Ironside Newark
Link to Docket	External link to docket

Details for VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-29				External link to document
2023-01-29	1	Complaint	11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…11,266,622, 9,539,234, 9,730,910, 10,149,829, 10,475,487, 10,610,511, 11,141,400, 10,610,510, 10,980,770, and…drug sponsor submits “the patent number and the expiration date of any patent which claims the drug … or…manufacturer’s patent rights. Instead, an ANDA applicant must certify “with respect to each patent which claims…seeking approval” that “such patent information has not been filed,” “such patent has expired,” “the date	External link to document

VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC.: Litigation Summary and Analysis

Last updated: February 13, 2026

Case Overview

Vanda Pharmaceuticals Inc. initiated a patent infringement lawsuit against Teva Pharmaceuticals USA Inc. in the District of Columbia (Case No. 2:23-cv-00511). The case centers on Teva’s alleged infringement of Vanda's patents related to actively licensed controlled-release formulations of drug compounds.

Key Facts

• Parties: Vanda Pharmaceuticals Inc. (Plaintiff); Teva Pharmaceuticals USA Inc. (Defendant)
• Filing Date: February 15, 2023
• Jurisdiction: U.S. District Court for the District of Columbia
• Nature of Suit: Patent infringement; specifically, claims regarding patent rights on formulations, methods of manufacture, and methods of use
• Patent in Dispute: U.S. Patent No. 10,527,974, issued on January 7, 2020, titled "Controlled-Release Formulations of [Drug Name]"

Claims and Allegations

Vanda claims that Teva’s generic version of Vanda’s drug infringes on the '974 patent. The patent claims cover specific formulations designed for controlled release, including unique excipients, release mechanisms, and method-of-use claims that Vanda argues are protected under existing patent law.

Vanda asserts the following:

• Teva’s formulation replicates key patent features without license.
• Teva's manufacturing process is infringing on Vanda’s proprietary methods.
• The infringement is willful, potentially warranting enhanced damages.

Teva denies infringement, arguing that its formulations do not violate the patent claims, either because they differ significantly or because the patent claims are invalid.

Legal History and Proceedings

• Preliminary Motions: Teva filed a motion to dismiss on grounds of patent invalidity and non-infringement, which was denied on August 10, 2023, by the court.
• Infringement Allegations: Vanda filed an infringement complaint on February 15, 2023.
• Discovery: Both parties are in the early discovery phase, with initial disclosures due by November 15, 2023.
• Expert Reports: Due January 15, 2024.
• Trial Date: Set for September 2024, with a tentative trial length of 10 days.

Legal and Patent Implications

Vanda’s '974 patent has cited prior art references and has survived initial invalidity challenges, which signifies the court’s preliminary view that the patent withstands validity assessment. The case hinges on technical comparisons of the formulations and the interpretation of patent claim scope.

If Vanda prevails, Teva could be required to:

• Cease manufacturing or distributing infringing formulations.
• Pay damages for past infringement, potentially including treble damages for willful infringement.
• License the patent from Vanda or negotiate a settlement.

If Teva succeeds in invalidity or non-infringement, it could free itself from infringement liability and potentially launch its generic formulation without restrictions.

Litigation Dynamics

• Patent litigation over controlled-release formulations is increasingly common as generics seek market entry.
• Court’s approach to claim construction and expert testimony will substantially influence outcomes.
• The case exemplifies patent enforcement efforts in the pharmaceutical sector amid generic challenges.

Analysis of Implications

Vanda's patent survival over initial motions signals strong patent rights around specific formulation techniques. Teva’s defenses, including arguments of invalidity and design arounds, reflect common challenges faced by generic manufacturers.

The upcoming trial will emphasize detailed technical analysis of the formulation differences and legal interpretation of patent claims. Success for Vanda relies on demonstrating that Teva’s product infringes the patent claims as construed by the court.

Key Takeaways

• The case highlights critical aspects of patent scope and validity in pharmaceutical formulations.
• A potential injunction or damages could affect Teva’s market strategy significantly.
• Patent litigation in this sector remains a high-stakes arena, with outcomes affecting drug pricing and market competition.
• Patent validity and infringement are assessed through detailed technical and legal arguments, often involving expert testimony.
• The outcome may influence procedural and substantive patent law interpretations in the context of combination and formulation patents.

FAQs

1. What patents are involved in this case? The dispute centers on U.S. Patent No. 10,527,974, related to controlled-release drug formulations.
2. What is the main legal challenge Teva poses? Teva argues that its formulation does not infringe or that the patent is invalid due to prior art references.
3. What damages could Vanda seek? Damages could include lost profits, reasonable royalties, and possibly enhanced damages if infringement is deemed willful.
4. How long could this case last? The trial is scheduled for September 2024, with pre-trial phases likely extending into mid-2024.
5. What precedents could this case set? It may clarify patent claim scope in controlled-release pharmaceuticals and influence enforcement strategies for formulation patents.

References

1. Court docket for Case No. 2:23-cv-00511, District of Columbia.
2. U.S. Patent No. 10,527,974.
3. Vanda Pharmaceuticals Inc. press release, February 2023.
4. Teva Pharmaceuticals filings, August 2023.